

Monday, February 28

7:30-8:30am Continental Breakfast, Grand Hall

Oral Session I: Retrovirus Infections I

Chairpersons: J.D. Gangemi, R.F. Schinazi

8:30am Welcome - George J. Galasso, President, ISAR
J. David Gangemi, Chairman, Local Organizing Committee

8:45 Plenary Speaker - Ashley Haase
"Pathogenesis of Human Immunodeficiency Virus Infection"
University of Minnesota Medical School, Minneapolis, MN

9:15 1. New Opportunities for Gene Therapy Against HIV. M. Essex, X. Yu, Z. Matsuda, C. Carini, and T.H. Lee. *Harvard School of Public Health, Boston, MA; and Johns Hopkins School of Hygiene and Public Health, Baltimore, MD, USA.*

9:30 2. The Viral Fusion Protein Leucine-Zipper, Coiled-Coil Domain: A Target for the Discovery of Novel Antivirals. S.R. Petteway, C. Wild, D. Bolognesi, and T. Matthews. *Trimeris, Inc., Durham, NC; and Duke University Medical Center, Durham, NC, USA.*

9:45 3. A Structural Model for HIV-1 Integrase. C.S. Ramanathan, E.W. Taylor, J.F. McDonald, and R.F. Schinazi. *University of Georgia, Athens, GA; and Emory University and Veterans Administration Medical Center, Decatur, GA, USA.*

10:00 Break

10:30 4. L-735,524: An Orally Bioavailable Human Immunodeficiency Virus Type 1 Protease Inhibitor. E.A. Emini, J.P. Vacca, B.D. Dorsey, W.A. Schleif, R.B. Levin, S.L. McDaniel, P.L. Darke, J.A. Zugay, J.C. Quintero, O.M. Blahy, E. Roth, V.V. Sardana, A.J. Schlabach, J.H. Condra, L. Gotlib, K. Holloway, J. Lin, J.-W. Chen, D. Ostovic, P.S. Anderson, and J.R. Huff. *Merck Research Laboratories, West Point, PA, USA*

10:45 5. Novel Aminoalcohol Inhibitors of HIV Protease. Design, Synthesis, and Characterization. J. Barrish, S. Ahmad, M. Alam, A. Ashfaq, G. Bisacchi, P. Chen, P. Cheng, R. Colonna, T. Dejneka, E. Gordon, J. Greytok, M. Hermsmeier, G. Humphreys, G. Jacobs, P.F. Lin, K. Lis, M. Marella, Z. Merchant, R. Morrison, T. Mitt, M. Obermeier, J. Pluscec, D. Ryono, M. Skoog, W. Slusarchyk, S. Spergel, J. Stevenson, C.Q. Sun, P. Taunk, J. Tino, G. Vite, B. Warrack, R. White, and R. Zahler. *Bristol Myer Squibb PRI, Princeton, NJ; and Wallingford, CT, USA.*

- 11:00 6. Kinase By-pass: A New Strategy for Antiviral Drug Discovery. C. McGuigan, R.N. Pathirana, P. Bellevergue, M.Davies, N. Mahmood, and A.J. Hay. *University of Southampton, Southampton; MRC Collaborative Centre, Mill Hill; and National Institute for Medical Research, London, UK.*
- 11:15 7. Novel Chiral Isomeric Nucleosides and Nucleotides: Synthesis, Enzymology and Anti-HIV Activity. V. Nair, L.B. Zintek, T.B. Sells, A.L. Jeffery, Z.M. Nuesca, D.F. Purdy, G.S. Jeon, R.B. Hamilton, P.J. Bolon, and S. Malany. *University of Iowa, Iowa City, Iowa, USA.*
- 11:30 8. Synthesis of Novel Oxathiolane and Dithiolane Nucleoside Analogues Possessing Anti-HIV Activity. N. Nguyen-Ba, L. Brasili, W.L. Brown, L. Chan, B. Zacharie, N. Lee, M. DiMarco, D. Lafleur, B. Belleau, P. Hopewell, and N. Cammack. *Bio Chem Therapeutic, Inc., Laval, Canada; and Glaxo Group Research, Ltd., Greenford, Middlesex, UK.*
- 11:45 9. Enantiomeric DDC Derivatives are Potent Inhibitors of HIV Replication in Cell Cultures. J.-L. Imbach, G. Gosselin, C. Math, M.-C. Bergogne, R.F. Schinazi, J.P. Sommadossi, A. Kirn, and A.-M. Aubertin. *Universit  de Montpellier II, France; Emory University, Atlanta, GA; University of Alabama, Birmingham, AL, USA; and Universit  Louis Pasteur, Strasbourg, France.*
- 12:00 Lunch

Oral Session II: Herpesvirus Infections I

Chairpersons: C.A. Laughlin and S.L. Sacks

- 1:30pm Plenary Speaker - Norbert Bischofberger
 "Development of Nucleotide Prodrugs as Antiviral Agents"
 GileadSciences, Inc. Foster City, CA, USA
- 2:00 10. Preclinical Evaluation of a Phosphorothioate Oligonucleotide with Potent Antiviral Activity against Human Cytomegalovirus. K.P. Anderson, R.F. Azad, V.B. Driver, H. Zhang, P. Cossum, J. Leeds, and D. Kornbrust. *ISIS Pharmaceuticals, Carlsbad, CA, USA.*
- 2:15 11. Antiviral Activity of Acyclic Nucleotide Phosphonate Analogs Derived from Azapurine Bases. A. Holy, H. Dvorakova, D. Hockova, J. Balzarini, R. Snoeck, and E. De Clercq. *Institute of Organic Chemistry and Biochemistry, Prague, The Czech Republic; and Katholieke Universiteit Leuven, Leuven, Belgium.*